Aprocitentan
Brand names: Tryvio · Active ingredient: Aprocitentan
In short: TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and
What is Aprocitentan used for?
TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO.
Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. …
âš Boxed warning (FDA's strongest warning)
TRYVIO is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients. Therefore in patients who can become pregnant, exclude pregnancy prior to initiation of TRYVIO.
Advise use of effective contraception before the start of TRYVIO, during treatment and for one month after stopping treatment.
When pregnancy is detected, discontinue TRYVIO as soon as possible
[see Dosage and Administration (2.2), Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1)]
.
Aprocitentan dosage
The recommended dosage of TRYVIO is 12.5 mg orally once daily.
Swallow tablets whole. TRYVIO may be taken with or without food.
If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take two doses on the same day.
Exclude pregnancy before initiating treatment with TRYVIO in females of reproductive potential [see Boxed Warning, Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.3)].
How to take Aprocitentan — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Embryo-Fetal Toxicity
Counsel patients who can become pregnant to use effective methods of contraception before treatment with TRYVIO, during treatment with TRYVIO, and for one month after treatment discontinuation. Patients who can become pregnant should have a negative pregnancy test prior to initiation of TRYVIO, .
Patients should be instructed to contact their healthcare provider if they suspect they may be pregnant. Patients should seek additional contraceptive advice from a gynecologist or similar expert as needed.
Educate and counsel patients who can become pregnant on the use of emergency contraception in the event of unprotected sex or contraceptive failure.
Advise pre-pubertal females and/or their guardian(s) to report any changes in their reproductive status immediately to their prescriber.
Lactation
Advise females not to breastfeed during treatment with TRYVIO .
Hepatotoxicity
Educate patients on signs of hepatotoxicity. …
Warnings & precautions
Do not take this medicine if: Use of TRYVIO is contraindicated in patients who are pregnant [see Dosage and Administration (2.2), Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].
TRYVIO is contraindicated in patients who are hypersensitive to aprocitentan or any of its excipients .
Based on data from animal reproduction studies with endothelin receptor antagonists (ERAs), TRYVIO may cause fetal harm when administered during pregnancy and is contraindicated for use in patients who are pregnant. The available human data for endothelin receptor antagonists do not establish the presence or absence of fetal harm related to the use of TRYVIO. Counsel patients who can become pregnant about the potential risk to a fetus. Obtain a pregnancy test prior to initiation of treatment with TRYVIO. Advise patients who can become pregnant to use effective contraception prior to initiation of treatment with TRYVIO, during treatment, and for one month after the final dose of TRYVIO. When pregnancy is detected, discontinue TRYVIO as soon as possible [see Dosage and Administration (2.2), Contraindications (4.1), Use in Specific Populations (8.1, 8.3)].
Elevations of aminotransferases and hepatotoxicity are known effects of ERAs, including TRYVIO. Elevations in alanine transaminase (ALT) or aspartate aminotransferase (AST) of greater than 5-fold upper limit of normal (ULN) were observed rarely in patients treated with aprocitentan in the clinical trial, including cases with positive rechallenge. There were no reports of patients with ALT and/or AST >3 × ULN and total bilirubin >2 × ULN or cases of liver failure observed in TRYVIO-treated patients in the clinical trials. …
Aprocitentan side effects
Clinically significant adverse reactions that appear in other sections of the labeling include:
Embryo-fetal toxicity
Hepatotoxicity
Fluid retention
Hemoglobin decrease
Decreased sperm counts
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of TRYVIO was evaluated in a placebo-controlled phase 3 clinical study (PRECISION, NCT03541174) in adults with uncontrolled BP (systolic blood pressure [SBP] ≥140 mmHg) despite the use of at least three antihypertensive medications.
In this study, 724 patients received any dose of aprocitentan, with 633 patients treated for at least 26 weeks, 192 patients for at least 47 weeks, and 99 patients for at least 48 weeks.
The most frequently reported adverse reactions to TRYVIO during the 4-week double-blind placebo-controlled treatment period (part 1) of the PRECISION study are presented in Table 1.
Adverse Reaction | 12.5 mg
N = 243
% | Placebo
N = 242
%
Edema/fluid retention | 9.1 | 2.1
Anemia | 3.7 | 0
Hypersensitivity Reactions
During the initial 4-week double-blind placebo-controlled treatment period (part 1), 0.8% of patients experienced an adverse reaction of hypersensitivity (i.e., rash, erythema, allergic edema) on TRYVIO compared to no reports in patients treated with placebo. …
About this medicine
TRYVIO (aprocitentan) is an endothelin receptor antagonist. The chemical name of aprocitentan is N-[5-(4-bromophenyl)-6- [2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-sulfamide. It has a molecular formula of C16H14Br2N6O4S and a molecular weight of 546.2 g/mol.
The structural formula is:
Aprocitentan is a white to off-white powder that is insoluble in water.
TRYVIO is available as film-coated 12.5 mg strength tablets for oral administration. The inactive ingredients in TRYVIO are croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose.
The film coating contains the following inactive ingredients: hydroxypropyl cellulose, iron oxide black, iron oxide red, iron oxide yellow, polyvinyl alcohol, silica colloidal hydrated, talc, titanium dioxide, and triethyl citrate.
How it works: Aprocitentan is an ERA that inhibits the binding of endothelin (ET)-1 to ETA and ETB receptors. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID dfe7a2ee-612c-4aba-834a-d68e6b59a0a6. Read the full official label on DailyMed.
Related medicines
Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Rosuvastatin Simvastatin Spironolactone